Leadership Shake-up at Lenstec: Can the New CEO Navigate the China Headwinds?
Lenstec
Optical Lens R&D, Supplier
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Bid-winning Atlas· Centralized Procurement Scaling | Ophthalmic Optometry Column
American Intraocular Lens ManufacturerLenstecAnnouncement of AppointmentBlake Michaels Appointed as New CEO, succeeding the retired founder John Clough.
This is not a simple personnel change, but a clear signal that imported brands are entering a phase of value reassessment in the Chinese market against the backdrop of rapid technological and market iteration.
What Michaels took over was not only a leading American company in optical technology, but also aNeed toChinese PartnersDeep Connections in Reshaping Growth Curves Under the New Policy Environment。
As the exclusive strategic partner of Lenstec in China,Haohai Bio-TechIn the 2025 annual report, based on the prudent principle, a goodwill impairment of 141 million yuan was accrued. This financial operation does not indicate a business regression but rather a proactive clearance of historical burdens and a solidification of the asset structure – to create more flexible strategic space in response to market changes such as the normalization of centralized procurement and the rise of Chinese brands.
Lenstec Leadership Change and Haohai Bio-SciTech Impairment Point to One Direction:Imported technologies and local leaders are proactively adjusting the pace of collaboration., shifting from the past "scale expansion" to a more sustainable "value symbiosis." For Haohai Biotech, this subtraction is precisely for the next more robust addition.
# Why Was This New CEO Selected?
First, let's look at Michaels' resume.
More than 40 years of experience in ophthalmic medical devices, spanningLaser, Implants, OptometryThree Key Areas: Leading U.S. sales of the WaveLight excimer laser at Alcon; as a founding team member of LenSx, driving the commercialization of femtosecond laser-assisted cataract surgery; and during tenure as CEO of Visioncare Inc. (now Samsara Vision), spearheading the transition of telescope technology into minimally invasive next-generation products.
Lenstec Chief Operating Officer Jimmy Chacko's comment was straightforward: "His experience, vision, and understanding of the ophthalmic community will enhance our ability to serve surgeons and patients worldwide."
Therefore, what Lenstec needs is not just a sales expert, but an operator who understands the entire "technology-clinical-commercial" chain.。
The core task of Lenstec at present isDrive the Expansion of the ClearView IOL Product Portfolio, especially the ClearView 3 multifocal lens. This signifies that the company is upgrading from "basic vision restoration" to "refractive solutions," and Michaels' commercialization experience with femtosecond lasers accumulated at LenSx aligns perfectly with this trend.
But the question is:Can Product Upgrades Offset Systemic Risks in the Chinese Market?
# The New CEO's Dilemma in China
For Michaels,The Most Challenging Market May Be ChinaLenstec products through Haohai Biotech subsidiaryShenzhen New Industry OphthalmologyDistributing sales, but in 2025, due to the impact of the artificial crystal centralized procurement, this business will face significant operational pressure.
According to Haohai Biotech's 2025 earnings快报, the national centralized procurement of intraocular lenses has entered the second phase of the two-year agreement period, coupled with the competitive cost and price advantages of domestically produced lenses.Lenstec Product Sales Price and Volume Both Show Downward TrendIn 2025, the total number of cataract surgeries in China decreased compared to 2024, with overall market demand falling.
Haohai Bio-Tech 2025 Full-Year Revenue: 2.473 Billion Yuan, Down 8.33% Year-on-Year; Net Profit: 251 Million Yuan, Down 40.3%. This marks the company's first dual decline in revenue and net profit in nearly five years. In the ophthalmology sector,Cataract surgery product line revenue was 316 million yuan, a decrease of 24.9%; intraocular lens revenue was 238 million yuan, a decrease of 27.3%.。
In terms of financial impact, Haohai Biotech provisioned approximately 140 million yuan for goodwill impairment of Shenzhen Xinchanye based on the expected price reduction in the second round of centralized procurement in the first half of 2026, and provisioned about 25 million yuan for intangible asset impairment of its U.S. subsidiary Aaren Scientific. The actual net profit of Shenzhen Xinchanye in 2024 was 22.0062 million yuan, which was less than half of the performance commitment (59.1 million yuan).
New CEO Needs to Restructure China Strategy：While maintaining the public hospital channel, respond to cost competition from domestically produced manufacturers (such as Aibo Medical), and adapt to the expected price reductions in the second round of centralized procurement.Michaels' China market experience accumulated at Alcon and LenSx will directly impact whether Lenstec can maintain its market share under price pressure.
# "Structural Dilemma" of Imported Brands
Lenstec's experience is not an isolated case. It reflects the collective challenges faced by imported intraocular lens brands in the Chinese market.
Dilemma 1: Loss of Pricing PowerThe centralized procurement compresses the product life cycle from "innovation-premium-popularization" to "access-volume-iteration." Multinational companies are accustomed to long-cycle clinical cultivation and high-margin-supported R&D investment, but under the centralized procurement rules, prices are determined by bidding rather than value.
Dilemma Two: Channel ReconstructionTraditional imported brands are highly dependent on public hospital ophthalmology departments and high-end private institutions. After centralized procurement, public hospitals have become the core channel due to their purchasing volume advantage, but imported brands are less price-competitive than domestically produced products in such channels. Shifting to private refractive centers? This would mean rebuilding the sales network and service system.
Dilemma Three: Product Matrix DisconnectionImported brands often have an advantage in the mid-to-high-end market, but the centralized procurement mainly covers basic and mid-range products. If a company doesn’t have enough high-end products (such as trifocal, EDOF, or toric IOLs) to sustain profitability, it may face the dilemma of being "trapped in centralized procurement at the low end while lacking presence in the high-end market."
Haohai Bio-Sci's response strategy is "Structural Optimization + Domestic Substitution"In 2026, the multifocal aspheric intraocular lens (pentafocal) was approved; in 2025, the hydrophobic molded toric aspheric intraocular lens was approved; the hydrophobic molded trifocal intraocular lens entered the registration application stage; the aqueous humor-permeable phakic posterior chamber intraocular lens entered the innovative approval channel.
Of course,It takes time for products to gain volume after approval, and the pace of the second round of bulk procurement will not stop.. But this is precisely another opportunity — the centralized procurement is forcing the industry to reshuffle, and also pushing companies with real technical reserves to accelerate their realization. Haohai's advantage lies in: the pipeline is already in place, the production capacity is being released, and the window period of centralized procurement happens to form a relay with the rhythm of product approval.Not passive response, but active positioning。
# Survival Rules in the Era of Centralized Procurement
CEO transitions in the medical device industry often signify a shift in strategic focus. Michaels' career trajectory from Visioncare, Alcon to Lenstec demonstrates a continued focus on "Technology Upgrade - Clinical Validation - Commercial Scaling"The high-value consumables pathway.
But the core contradiction in China's ophthalmology market is no longer technological iteration, but ratherReconstruction of Payment Ability——Centralized procurement compresses the product lifecycle from "innovation-premium-popularization" to "access-volume-iteration," posing a systemic challenge to multinational companies accustomed to long-cycle clinical development.
The real test for Michaels lies in:Can the channel model transformation in the Chinese market be completed within 18-24 months?. Options include:
Establishing joint ventures with local companies to achieve localized production for cost advantages;
Promote ClearView into the special review channel for innovative medical devices in exchange for pricing protection;
Shift the focus away from public hospitals towards private ophthalmic institutions and refractive surgery centers.
Each option involves a recalibration of the global pricing system and requires strategic decision-making at the board level.
# From "Surgical Consumables" to "Refractive Solutions"
The value of the Lenstec leadership change lies in its revelation of the deep-seated changes in the intraocular lens industry:Product attributes are evolving from "surgical consumables" to "refractive solutions."。
The goal of cataract surgery is no longer just "restoring sight," but "full-range vision and glasses-free living." This means:
The Logic of Patient Payment is Changing. Basic intraocular lenses are covered by medical insurance/purchasing consortiums, while premium lenses are paid for by patients out-of-pocket or covered by commercial insurance. Market differentiation will intensify in the future — low-end products will focus on volume, high-end products will target profit margins, and the mid-range segment will face dual pressure.
The Logic of Doctor Decision-Making is ChangingAgainst the backdrop of DRG/DIP cost control, when doctors choose intraocular lenses, they must consider not only the clinical outcomes but also the medical insurance reimbursement standards, the hospital’s cost structure, and the patient's ability to pay out-of-pocket. The rise of preloaded products is precisely because they "make surgery smoother, more stable, and more convenient," creating hidden value under the same payment standards.
The Logic of Enterprise Competition is Changing. Simple product competition is giving way to comprehensive capabilities of "product + service + data." Whoever can provide a complete solution from preoperative screening, intraoperative navigation to postoperative follow-up will be able to build barriers in the high-end market.
Michaels' resume happens to align with these trends. The femtosecond laser technology he promoted at LenSx is precisely the key infrastructure for refractive cataract surgery; his experience with the minimally invasive transformation at Visioncare is also applicable to the current upgrade from "large incision implantation" to "precise refractive correction."
But resumes are one thing, and execution is another.In the Chinese market, imported brands need not another "global strategist," but a "local operator" who understands China's medical insurance, the rules of centralized procurement, and channel restructuring.。
Ophthalmology Solutions Case
